Valeant CEO Hospitalization, Medical Leave Vexes Investors
This article was originally published in Scrip
Executive Summary
Shares of Valeant Pharmaceuticals International Inc. sank about 11% on Dec. 28 over concerns about the hospitalization due to a "severe case of pneumonia" and subsequent medical leave of the company's CEO Michael Pearson.